Navigation Links
Medication may improve portal hypertension
Date:4/1/2009

In a new study, a therapeutic agent called sorafenib dramatically improved the condition of rats with portal hypertension. The drug is already approved in several countries for treatment of kidney and liver cancer, and it may be time to consider it for patients suffering from advanced portal hypertension, the authors suggest. Their findings are in the April issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (www.interscience.wiley.com).

Portal hypertension is the most significant complication for patients with liver cirrhosis. It can become serious and life-threatening, and we do not have many effective ways to treat it. Researchers have considered antiangiogenic drugs, which inhibit the growth of new blood vessels, since such vascular formation is a hallmark of portal hypertension, as they have previously demonstrated. One such drug is sorafenib, a powerful multikinase inhibitor that can be taken orally.

Researchers, led by Mercedes Fernandez from the Institute of Biomedical Research IDIBAPS of Barcelona, examined the effects of sorafenib on rats with portal hypertension induced by partial portal vein ligation or bile duct ligation.

"Our present study is the first to determine if the multiple kinase inhibitor sorafenib causes beneficial effects on the splanchnic, intrahepatic and systemic circulations, and on portosystemic collateral vessels in two different experimental models of portal hypertension," they report.

The rats in the study took sorafenib orally every day for two weeks. They showed no signs of toxicity or adverse effects and the researchers noted numerous improvements in their condition. They had an 80 percent decrease in the growth of new blood vessels and marked lessening of circulation in the areas around the liver. The treatment also decreased portal pressure by 25 percent, and liver fibrosis and inflammation improved.

"Taking into account the limitations of translating animal study results into humans, we believe that our findings will be stimulating for consideration of sorafenib as an effective therapeutic agent in patients suffering from advanced portal hypertension," the authors conclude.

An accompanying editorial by Vijay Shah of the Mayo Clinic and Jordi Bruix of Barcelona notes the promise of the findings by Mejias and colleagues. "It is obvious that a new avenue for pharmacologic intervention in patients with cirrhosis has emerged," they write.

They encourage the evaluation of antiangiogenesis therapy in patients with cirrhosis and portal hypertension, though saying it "will need a very careful approach." Researchers will have to determine the optimal dosage that maintains efficacy while remaining tolerable and safe for patients. They must also consider the impact on cardiac function.

"The challenge is there and it is time to move ahead," Shah and Bruix conclude.


'/>"/>

Contact: Sean Wagner
medicalnews@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. American Society of Anesthesiologists - 2,211 Patient Deaths From OVER Medication
2. Fish in U.S. Rivers Tainted With Common Medications
3. Pilot Study Using Video Cell Phones for Mobile Direct Observation Treatment (MDOT) to Monitor Medication Compliance of TB Patients
4. FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
5. New research suggests common anti-seizure medications may increase risk of cardiovascular problems
6. HealthyPlace.com, the Largest Consumer Mental Health Site, Launches Mediminder, a Free Medication Reminder Tool for the More Than 30 Million People Who Suffer From Depression, Anxiety, Bipolar Disorder and Other Mental Health Conditions
7. Consumer Reports Poll: 66% of Americans Blindsided by Cost of Drugs; Many Not Taking Needed Medications
8. The Detroit Medical Center Pioneers New EMR System Preventing Medication Mistakes
9. Injected Medication Errors a Major Problem
10. Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement
11. ADA Informs Patients About Osteoporosis Medications and Oral Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Many RNA binding ... principles, the research team developed expressRNA, a web platform encompassing computational tools for ... at nucleotide resolution the ‘RNA maps’, which demonstrate that RBPs bind to specific ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage (UA), ... seven new products designed to create tailored looks and athleisure-inspired outfits. UA Flex fabric ... easy care stretch twill. , With trendy looks hitting the medical community, UA Flex ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... agency, recently became re-accredited by the Joint Commission, which accredits and certifies ... and certification is recognized nationwide as a symbol of quality that reflects an ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River ... aboard the line’s latest all-inclusive boutique ship, S.S. Joie de Vivre . What ... specifically for cruising France’s Seine River and designed small enough to dock directly in ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water advocate Sharon Kleyne ... Hour Power of Water, Global Climate Change and Your Health on VoiceAmerica sponsored ... and how it affects the human eyes. , According to Sharon Kleyne ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... Pa. , June 19, 2017  Researchers from ... today that they will host a live, complimentary webinar ... from the benchtop to the real world" on Wednesday ... EDT. This webinar will feature interviews ... rare look into the manipulation techniques abusers use to ...
(Date:6/14/2017)...  ivWatch LLC, a medical device company focused on ... is pleased to announce it was the Bronze Winner ... and Equipment at the 2017 Medical Design Excellence Awards ... The award was presented by Medical Device and Diagnostics ... New York during MD&M East, ...
(Date:6/13/2017)... WARSAW, Ind. , June 13, 2017 Zimmer ... in musculoskeletal healthcare, today announced that the U.S. Food and ... Letter dated June 3, 2015 relating to its ... "The successful clearance of ... China manufacturing facility is a measure of the ...
Breaking Medicine Technology: